DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Bucillamine
Bucillamine
Modifying Antirheumatic Drugs in Active Rheumatoid Arthritis: a Japan Phase 3 Trial (HARUKA)
Study Protocol);
Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
24/3 Pag 121 Ok X WENDY
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
Efficacy and Toxicity of Methotrexate (MTX)
Alphabetical Listing of ATC Drugs & Codes
Small Molecule DMARD Therapy and Its Position in RA Treatment
Mechanisms of Action of Second-Line Agents and Choice of Drugs in Combination Therapy
Assessment Report
Serum Matrix Metalloproteinase-3 As Predictor of Joint Destruction in Rheumatoid Arthritis, Treated with Non-Biological Disease Modifying Anti-Rheumatic Drugs
WO 2012/175518 Al 27 December 2012 (27.12.2012) P O P C T
(CD-P-PH/PHO) Report Classification/Justifica
Yellow Nail Syndrome in Rheumatoid Arthritis: an Aetiology Beyond Thiol Drugs Ajay Kumar Mishra1,*, Anu Anna George2 and Leni George2
Journal of Bone Biology and Osteoporosis Iguratimod, a Synthetic Disease Modifying Anti- Rheumatic Drug (Sdmard), and Various Dmards Suppress Joint Destruction
WHO Pharmaceuticals
Chelation Therapy in the Treatment of Metal Intoxication Page Left Intentionally Blank Chelation Therapy in the Treatment of Metal Intoxication
KDIGO Clinical Practice Guideline for Glomerulonephritis
Top View
Study Protocol);
Australian Statistics on Medicines 2009
Wo 2007/044693 A2
Medications, Dry Mouth and Dental Caries Among Older People: a Longitudinal Study
Centre for Reviews and Dissemination
Mechanism of Action of the Disease
Systematic Review of Combination DMARD Therapy in Rheumatoid Arthritis Beusekom I. Van1, C. Maclean2, C.F. Allaart3, and F.C. Br
[Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
Methotrexate and Oral Antirheumatic Drugs
A1298C Polymorphism 185 Abnormal Color Vision 87 Acetylcysteine 12
Establishment of Framework for Classification/Categorisation and Labelling of Medicinal Drugs and Driving
Study of the Effect of Bucillamine on the Early and Late Phase of Hepatic Ischaemia Reperfusion Injury